Abstract A higher frequency (25%) of gastro-
reported in patients over 5 years old with cystic fibrosis compared with controls without cystic fibrosis. It was believed that GOR was caused by the complications of cystic fibrosis. We looked for GOR in all 26 children younger than 60 months who had cystic fibrosis diagnosed. They had a classical genetic profile and the usual scattered clinical manifestations for age. GOR was confirmed in 21 (81%): 20 by abnormal pH tracings and in one on a clinical basis. After at least one month of adjusted cystic fibrosis treatment, antireflux treatment (cisapride) was given to 16 patients and variables of GOR improved dramatically. Weight gain was significant and recurrent cough and wheeze disappeared. One year later half of the patients still suffered from GOR. GOR is a major problem in the early life of those with cystic fibrosis and is not the consequence of either respiratory or gastrointestinal complications as it improves with age whereas cystic fibrosis becomes worse with age.
Bendig et al in 1982' and Scott et al in 19852 described a high frequency of gastrooesophageal reflux (GOR) in older children and adults with cystic fibrosis compared with its frequency in the population in general.3 ' Vinocur et al found in 1985 a high frequency of GOR in children with cystic fibrosis under the age of 20 months.5 However in all these studies only those with cystic fibrosis and clinical evidence of GOR were investigated.
Prinsen and Thomas reported a study on infants with cystic fibrosis who had been receiving cisapride for clinically established GOR and who showed a higher weight gain than they would have expected solely from the relief of GOR. They concluded that cisapride, a gastrointestinal prokinetic stimulant known to be effective in the treatment of GOR,7-9 had some anabolic action in patients with cystic fibrosis. Subsequent studies did not confirm this hypothesis.'0 " In these two studies no investigations were performed to ascertain the presence of GOR before the administration of cisapride.
GOR is known to cause gastrointestinal and respiratory complications in patients without cystic fibrosis. 12"6 The aim of our study was to investigate whether GOR starts very early in life and gradually complicates the underlying cystic fibrosis disease or whether GOR is the consequence of other cystic fibrosis complications. Up to the present GOR has hteen considered to result from respiratory and abdominal involvement, as suggested in a recent review article. '7 If this were true the frequency of GOR would increase with age. Also in the younger patients with cystic fibrosis there would be a propensity towards the same frequency as in the population in general. We decided to investigate the oesophagus of all babies and infants in whom cystic fibrosis was diagnosed. As far as we know investigations by pH tracings over about 20 hours have not been performed systematically in infants with cystic fibrosis before. In a first series of 10 children with cystic fibrosis who were less than 5 years old we found GOR in all of them. 8 Surprised by these results we enlarged our series and arranged long term follow up of all cases. In 1989 we published the preliminary data of the pH tracings and reflux scintigraphies shortly after the diagnosis of cystic fibrosis in 23 patients younger than 5 years old. 9 We now report in detail all available data including long term follow up in 26 patients.
Patients and methods PATIENTS (TABLE 1) As Scott et al had already studied older children with cystic fibrosis,2 we considered only patients younger than 5 years when entering the study. From 1986 on all 26 consecutive babies and Cisapride (Prepulsid, Janssen Pharmaceutica) is a new potent gastrointestinal prokinetic drug that increases the tone of the lower oesophageal sphincter. The mechanism of action of the drug is believed to be enhanced release of acetylchololine from the myenteric plexus. It has been shown to be effective in the treatment of GOR, gastroparesis, and chronic constipation.7-9 We have used it previously in infants and children suffering from GOR and respiratory disease but without cystic fibrosis. 26 27 Cisapride was available in syrup form at the concentration of 1 mg/ml and the usual dosage schedule was 0-2 mg/kg body weight four times a day 30 minutes before each meal. In some infants we needed to increase this dose to 0 3 mg/kg. Those with more than four meals received the fourth dose before the last evening meal.
The agreement of the hospital's ethical committee for this open treatment trial was obtained and the parents gave informed consent.
PATIENT OBSERVATION All infants were first observed for some time (at least one month) under a classic cystic fibrosis treatment considered optimal: (1) Mucolytic aerosols and physical treatment for bronchial toilet, both at least once a day, irrespective of respiratory symptoms. (2) 
0-3 (4) lit Respiratory infections 8 3 Genetic investigation: A f508 homozygote (p=0007), and for the number of refluxes longer than five minutes r= -0x4127 (p=0040).
The Newzv insights on gastro-oesophageal reflux in cysticfibrosis by longitudinalfollow up cystic fibrosis also contrast with our previous observation of children and infants with reflux pathology and respiratory disease not associated with cystic fibrosis. In these children the pH variables were much less disturbed before treatment but the response to cisapride, though significant, was less dramatic27 and some needed Nissen fundoplication to achieve respiratory improvement.
The beneficial effects of cisapride observed initially by Prinsen and Thomas in some babies with cystic fibrosis could be due to the correct treatment of their GOR because of the great potential effect of the drug on this defect in those with cystic fibrosis.6 Cisapride has probably no effect at all in those with cystic fibrosis without GOR, which may explain the disappointing results of Smith et al'0 and of Santamaria et al," both of whom used cisapride without discrimination even in older patients with cystic fibrosis, some of whom probably did not stiffer from GOR.
After the rapid relapse of respiratory complications in patient 2 when cisapride was stopped three months after first given, we decided on treatment for one year in all new patients in order to avoid too many repeated pH measurements. The safety of cisapride has already been established.7-9 27 GOR even in the population in general can induce a variety of severe digestive and respiratory complications and be responsible for growth retardation.4 17 31 Patients with cystic fibrosis are susceptible to the same complications, starting in early life, but these can result both in irreversible lung damage and increased malnutrition. It is worth while mentioning that the occasional oesophagoscopy performed in three cystic fibrosis patients with reflux indices larger than 40% did not show oesophagitis, either on direct inspection or on the microscopic examination of the mucosal biopsy specimen and therefore we abandoned oesophagoscopy. The limited number of patients and the relatively short duration of the follow up of the present sample does not allow any objective interpretation of antireflux treatment on the overall course, except that all these patients benefited from the intensive and optimal cystic fibrosis treatment. It might be anticipated that appropriate antireflux treatment in cystic fibrosis with concomitant GOR can improve long term prognosis of cystic fibrosis. These issues are under further investigation and need many years of observation on a larger sample than the present one.
All these data seem to indicate that GOR in cystic fibrosis is caused neither by the respiratory nor the intestinal problems that have been the generally accepted explanations until now. This is because GOR can occur very early after birth and tends to decrease with age whereas respiratory problems in cystic fibrosis increase with time. We suggest that all cystic fibrosis babies and infants should benefit from systematic investigations for GOR, and also older cystic fibrosis patients if their treatment yields an unexpectedly bad response. Some of our older patients with reflux successfully responded to cisapride but are not reported here as they are not systematically investigated.
Further studies are warranted to answer the questions: Why does GOR occur much more frequently in babies and infants with cystic fibrosis than in the normal population? Why, despite the tendency of GOR to disappear in the population in general, does it remain in many patients with cystic fibrosis? To answer these questions the long term observation of those with cystic fibrosis who initially do not have GOR, though they seem to be less common, is at least as essential as the continuous observation of those with GOR. Indeed two different populations might exist: (i) infants who reflux early as described here in this paper and (ii) infants who reflux as a result of underlying respiratory or nutritional complications.
